Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CVM vs AGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AGEN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)
AGEN Overall Winner
6-Pillar Tally: CVM 0 – 5 AGEN (1 Tie)
Matrix Metrics: CVM 3 – 7 AGEN
As of Nov 16, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas AGEN carries 51.5/100 (HOLD) at $6.34 (3.7x Forward P/E, 38.9% operating margin).
- Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. AGEN 51.5/100 HOLD), AGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (38.9% vs. 0.0% operating margin) and revenue trajectory (+4.1% vs. -62.7% YoY).
- Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CVM vs AGEN
CVM
Cel-Sci Corporation
$1.59
+24.22% 1D
Market Cap
$20.9M
TTM Revenue
$28,558
Forward P/E
23.0x
Beta / 30D Vol
0.65β · 120% Vol
Unified Composite Score
56.6
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
AGEN
Head-to-Head Winner
Agenus Inc.
$6.34
-5.79% 1D
Market Cap
$310.8M
TTM Revenue
$34M
Forward P/E
3.7x
Beta / 30D Vol
1.60β · 76% Vol
Unified Composite Score
51.5
HOLD
Tech 49.0
Fund 55.0
Flow 66.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CVM 0 – 5 AGEN)
1. Valuation Multiples
AGEN
Forward P/E
23.0x
3.7x
Trailing P/E
23.0x
29.9x
PEG Ratio
1.12x
1.44x
EV / Revenue
N/M
8.9x
2. Growth & Scale
AGEN
Revenue Growth (YoY)
-62.7%
+4.1%
Earnings Growth (YoY)
+0.0%
-99.0%
TTM Revenue (USD)
$28,558
$34M
Market Cap
$20.9M
$310.8M
3. Profitability & Quality
AGEN
Gross Margin
N/A
N/A
Operating Margin
0.0%
38.9%
Net Profit Margin
0.0%
30.8%
Return on Equity (ROE)
-252.5%
-1278.8%
4. Balance Sheet & Cash Flow
AGEN
Cash Generation (TTM)
-$17M
-$35M
Cash Flow Margin
N/A
-103.7%
Net Cash / Leverage
$6.6M Net Debt (1.24x D/E)
$9.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AGEN
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
N/A (N/A)
95.2% (11th %ile)
Put/Call OI Skew
N/A
0.02x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CVM (3) vs AGEN (7)| Institutional Metric | CVM | AGEN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $20.9M | $310.8M | AGEN | |
| Trailing P/E Ratio | 23.0x | 29.9x | CVM | |
| Forward P/E Ratio | 23.0x | 3.7x | AGEN | |
| Revenue Growth (YoY) | -62.7% | +4.1% | AGEN | |
| Operating Margin (TTM) | 0.0% | 38.9% | AGEN | |
| Net Profit Margin | 0.0% | 30.8% | AGEN | |
| Return on Equity (ROE) | -252.5% | -1278.8% | CVM | |
| 52-Week Range Position | 10% ($1–$8) | 48% ($3–$10) | AGEN | |
| Beta / 30D Volatility | 0.65β · 120% Vol | 1.60β · 76% Vol | AGEN | |
| Unified Institutional Score | 56.6 / 100 (HOLD) | 51.5 / 100 (HOLD) | CVM | |
| Trailing 12M Revenue (USD) | $28,558 | $34M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | 1.12x PEG · N/M EV/Rev | 1.44x PEG · 8.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($6.6M Net Debt (1.24x D/E)) | -$35M ($9.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AGEN +16.14 pp
3M Horizon
CVM +15.8 pp
6M Horizon
AGEN +108.19 pp
1Y Horizon
AGEN +122.06 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | AGEN Revenue | CVM Op. Margin | AGEN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $40M | N/A | -336.6% | AGEN |
| FY2019 | N/A | $150M | N/A | -46.7% | AGEN |
| FY2020 | N/A | $90M | N/A | -133.0% | AGEN |
| FY2021 | N/A | $300M | N/A | 8.7% | AGEN |
| FY2022 | N/A | $100M | N/A | -183.0% | AGEN |
| FY2023 | N/A | $160M | N/A | -102.1% | AGEN |
| FY2024 | N/A | $100M | N/A | -116.4% | AGEN |
| FY2025 | N/A | $110M | N/A | -17.7% | AGEN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CVM
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AGEN
BREAKDOWN
Current IV
95.2%
IV Percentile
11th %ile
Put/Call OI Skew
0.02x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CVM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
AGEN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CVM vs AGEN Key Questions & Quantitative Answers
As of Nov 16, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas AGEN carries 51.5/100 (HOLD) at $6.34 (3.7x Forward P/E, 38.9% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. AGEN 51.5/100 HOLD), AGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (38.9% vs. 0.0% operating margin) and revenue trajectory (+4.1% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AGEN leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with AGEN at +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CVM cumulative revenue shifted N/A while AGEN shifted +175.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGEN.
AGEN screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas AGEN trades at 3.7x Forward P/E, 29.9x Trailing P/E, 1.44x PEG, and 8.9x EV/Revenue (-103.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus AGEN (-1278.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, AGEN carries 95.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.60β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AGEN vs CVM · Reverse Pair
CVM vs BCRX
· Sector Peer
AGEN vs BCRX
· Sector Peer
AGEN vs CLDX
· Sector Peer
AGEN vs ACAD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma